"10.1371_journal.pone.0117973","plos one","2015-02-11T00:00:00Z","Donna G Crenshaw; Karen Asin; William K Gottschalk; Zhifeng Liang; Nanyin Zhang; Allen D Roses","Zinfandel Pharmaceuticals, Inc., Chapel Hill, NC, United States of America; Takeda Development Center Americas, Inc., Deerfield, IL, United States of America; Biomedical Engineering Department, The Pennsylvania State University, University Park, PA, United States of America","Conceived and designed the experiments: DGC KA ADR NZ WKG. Performed the experiments: NZ ZL. Analyzed the data: NZ KA DGC. Contributed reagents/materials/analysis tools: NZ KA. Wrote the paper: DGC KA NZ. Contributed to the editing of the manuscript: DGC KA NZ WKG ADR.","The authors have read the journals policy and the authors of this manuscript have the following competing interests: Takeda Development Center Americas, Inc. provided the funding for this study. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials for this study. KA is a paid employee of Takeda Development Center Americas, Inc. ADR is the CEO of Zinfandel Pharmaceuticals, Inc. Takeda and Zinfandel Pharmaceuticals, Inc. are in a business alliance to conduct a clinical trial of pioglitazone for the purpose of gaining marketing approval for the drug for the delay of onset of Alzheimers disease. DGC and WKG are paid consultants of Zinfandel. NZ is a member of the PLOS ONE Editorial Board. This does not, however, alter the authors adherence to PLOS ONE Editorial policies and criteria. ZL and NZ report that no other competing interests exist.","2015","02","Donna G Crenshaw","DGC",6,TRUE,5,2,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
